# Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary

> **NCT03206177** · PHASE1 · COMPLETED · sponsor: **University of Oklahoma** · enrollment: 26 (actual)

## Conditions studied

- Carcinosarcoma, Ovarian

## Interventions

- **DRUG:** Galunisertib
- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT03206177
- **Lead sponsor:** University of Oklahoma
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-23
- **Primary completion:** 2021-07-28
- **Final completion:** 2024-02-13
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2024-08-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03206177

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03206177, "Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03206177. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*